Exelixis Inc (EXEL) 4.19 $EXEL
Exelixis (EXEL) Showing Signs Of A Dead Cat Bounce Today
at The Street - Fri Aug 01, 8:45AM CDT
Trade-Ideas LLC identified Exelixis (EXEL) as a "dead cat bounce" (down big yesterday but up big today) candidate
Exelixis Announces Second Quarter 2014 Financial Results
Business Wire - Thu Jul 31, 3:14PM CDT
Exelixis, Inc. (Nasdaq:EXEL) today reported financial results for the quarter ended June 30, 2014.
Complete Response Letter from FDA, Positive Opinion on Drug, Technical Update, Financial Result Release, and Clinical Trial Results - Research Reports on AcelRx, Horizon, Gilead, AbbVie and Exelixis
PR Newswire - Thu Jul 31, 8:20AM CDT
Today, Analysts Review released its research reports regarding AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), Horizon Pharma Inc. (NASDAQ: HZNP), Gilead Sciences Inc. (NASDAQ: GILD), AbbVie Inc. (NYSE: ABBV) and Exelixis Inc. (NASDAQ: EXEL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5305-100free.
Biotech Companies Release Quarterly Financials and Announce Earnings Release Dates - Research Reports on Illumina, Alexion, Questcor, Jazz Pharmaceuticals and Exelixis
PR Newswire - Tue Jul 29, 7:40AM CDT
Today, Analysts Review released its research reports regarding Illumina, Inc. (NASDAQ: ILMN), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Exelixis, Inc. (NASDAQ: EXEL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5214-100free.
'Mad Money' Lightning Round: Don't Sell General Electric Just Yet
at The Street - Tue Jul 29, 5:00AM CDT
Cramer thinks FleetCor Technologies is fabulous and he's not giving up on Exelixis at the moment.
Jim Cramer's 'Mad Money' Recap: Monday Merger Mania
at The Street - Mon Jul 28, 7:08PM CDT
Cramer looks at Dollar Tree buying Family Dollar and Zillow buying Trulia and wonders who's next.
Exelixis Up 6.6%, Shares Break Through Resistance (EXEL)
Comtex SmarTrend(R) - Mon Jul 28, 11:38AM CDT
Exelixis (NASDAQ:EXEL) is one of today's best performing low-priced stocks, up 6.6% to $4.47 on 1.0x average daily volume. Exelixis has traded 5.4 million shares thus far today, vs. average volume of 5.1 million shares per day. The stock has outperformed the Dow (6.6% to the Dow's -0.2%) and outperformed the S&P 500 (6.6% to the S&P's -0.3%) during today's trading.
Exelixis (EXEL) Jumps: Stock Adds 11.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 8:39AM CDT
Exelixis, Inc. (EXEL) was a big mover last session, as its shares rose over 11% on the day.
Traders Get Bullish on Shares of Exelixis, Shares Up 6.1% (EXEL)
Comtex SmarTrend(R) - Thu Jul 24, 10:38AM CDT
Exelixis (NASDAQ:EXEL) is one of today's best performing low-priced stocks, up 6.1% to $4.01 on 1.0x average daily volume. Thus far today, Exelixis has traded 4.8 million shares, vs. average volume of 4.7 million shares per day. The stock has outperformed the Dow (6.1% to the Dow's 0.1%) and outperformed the S&P 500 (6.1% to the S&P's 0.2%) during today's trading.
Is this Exelixis Stock's Worst Nightmare?
Cory Renauer, The Motley Fool - Motley Fool - Tue Jul 22, 4:00PM CDT
Oncology specialist Exelixis shares have been on a roller coaster over the past several years. The company has an impressive stable of clinical stage candidates, but its pipeline has yet to prove itself in the clinic, or on the market. Having lots...
This Week in Biotech: AbbVie's Five-Leaf Clover and Exelixis' Excellent Results
Sean Williams, The Motley Fool - Motley Fool - Sat Jul 19, 1:32PM CDT
With the SPDR S&P Biotech Index up 18% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
SEC Filings, Positive Trial Results, Technical Updates, and sNDA Updates - Analyst Notes on Questcor, Exelixis, InterMune, Progenics and Arrowhead
PR Newswire - Fri Jul 18, 7:40AM CDT
Today, Analysts Review released its analysts' notes regarding Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Exelixis, Inc. (NASDAQ: EXEL), InterMune Inc. (NASDAQ: ITMN), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX) and Arrowhead Research Corp. (NASDAQ: ARWR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4874-100free.
Exelixis, Inc., Analyst Report; The Upside Potential is Worth the Risk by BrokerBank Securities, Inc.
PR Newswire - Thu Jul 17, 2:05PM CDT
Exelixis, Inc. (Nasdaq: EXEL) is a development stage biotech company. EXEL developed two cancer treatments cabozantinib (Cabo, Cometriq) and cobimetinib (Cobi). Both use small molecules as the active component. The company has a partnership with Roche to commercialize, market and distribute cobi. Cobi is expected to earn approval in the treatment of melanoma by late 2015, after positive phase-three trial results earlier this week. Cabo is marketed and distributed in the U.S. by EXEL, and in Europe by Sobi. Sobi receives an undisclosed management fee. European revenues are expected in Q2 after a March European approval. Cabo is currently only approved to treat a specific type of thyroid cancer, MTC. There are between 500-700 new cases per year in the U.S., and treatment costs $10,395 for a 28-day supply. In addition, the company has five phase-three trials for various cancer treatments. On top of those, the company has numerous partnerships with other drug companies, and multiple treatments in phase two trials. EXEL has a huge pipeline of potential uses for cabo and cobi.
Should Roche Buy Exelixis?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Wed Jul 16, 4:00PM CDT
Investors in Roche and Exelixis saw a bit of positive news Monday, when Roche announced that its phase 3 combo study of MEK inhibitor cobimetinib (licensed from Exelixis) and BRAF inhibitor Zelboraf met it primary endpoint. No details were...
Exelixis to Release Second Quarter 2014 Financial Results on Thursday, July 31, 2014
Business Wire - Wed Jul 16, 3:05PM CDT
Exelixis, Inc. (NASDAQ: EXEL) announced today that its second quarter 2014 financial results will be released on Thursday, July 31, 2014 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call to discuss the Company's financial results for the second quarter 2014 and provide a general business update. The conference call will be accessible via the Internet from the Company's website.
Time to Fall Back in Love With Exelixis Inc.?
Brian Orelli, The Motley Fool - Motley Fool - Tue Jul 15, 4:34PM CDT
Exelixis spiked up 23% Monday after its partner Roche announced that the duo's cancer drug passed a phase 3 trial. Some speculation about a potential buyout by Roche also seems to have contributed to Exelixis' increased value. Let's cover...
Most active Nasdaq-traded stocks
AP - Tue Jul 15, 12:20PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
Critical Alerts For Exelixis, Rocket Fuel, Netflix, Johnson & Johnson, and Achillion Pharmaceuticals Released By InvestorsObserver
PR Newswire - Tue Jul 15, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for EXEL, FUEL, NFLX, JNJ, and ACHN.
Exelixis (EXEL) Soars: Stock Adds 23% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 15, 8:04AM CDT
Exelixis, Inc. (EXEL) was a big mover last session, as the company saw its shares rise 23% on the day.
Exelixis (EXEL) Showing Signs Of A Dead Cat Bounce Today
at The Street - Fri Aug 01, 8:45AM CDT
Trade-Ideas LLC identified Exelixis (EXEL) as a "dead cat bounce" (down big yesterday but up big today) candidate
Exelixis Announces Second Quarter 2014 Financial Results
Business Wire - Thu Jul 31, 3:14PM CDT
Exelixis, Inc. (Nasdaq:EXEL) today reported financial results for the quarter ended June 30, 2014.
Complete Response Letter from FDA, Positive Opinion on Drug, Technical Update, Financial Result Release, and Clinical Trial Results - Research Reports on AcelRx, Horizon, Gilead, AbbVie and Exelixis
PR Newswire - Thu Jul 31, 8:20AM CDT
Today, Analysts Review released its research reports regarding AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), Horizon Pharma Inc. (NASDAQ: HZNP), Gilead Sciences Inc. (NASDAQ: GILD), AbbVie Inc. (NYSE: ABBV) and Exelixis Inc. (NASDAQ: EXEL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5305-100free.
Biotech Companies Release Quarterly Financials and Announce Earnings Release Dates - Research Reports on Illumina, Alexion, Questcor, Jazz Pharmaceuticals and Exelixis
PR Newswire - Tue Jul 29, 7:40AM CDT
Today, Analysts Review released its research reports regarding Illumina, Inc. (NASDAQ: ILMN), Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Exelixis, Inc. (NASDAQ: EXEL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5214-100free.
'Mad Money' Lightning Round: Don't Sell General Electric Just Yet
at The Street - Tue Jul 29, 5:00AM CDT
Cramer thinks FleetCor Technologies is fabulous and he's not giving up on Exelixis at the moment.
Jim Cramer's 'Mad Money' Recap: Monday Merger Mania
at The Street - Mon Jul 28, 7:08PM CDT
Cramer looks at Dollar Tree buying Family Dollar and Zillow buying Trulia and wonders who's next.
Exelixis Up 6.6%, Shares Break Through Resistance (EXEL)
Comtex SmarTrend(R) - Mon Jul 28, 11:38AM CDT
Exelixis (NASDAQ:EXEL) is one of today's best performing low-priced stocks, up 6.6% to $4.47 on 1.0x average daily volume. Exelixis has traded 5.4 million shares thus far today, vs. average volume of 5.1 million shares per day. The stock has outperformed the Dow (6.6% to the Dow's -0.2%) and outperformed the S&P 500 (6.6% to the S&P's -0.3%) during today's trading.
Exelixis (EXEL) Jumps: Stock Adds 11.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jul 25, 8:39AM CDT
Exelixis, Inc. (EXEL) was a big mover last session, as its shares rose over 11% on the day.
Traders Get Bullish on Shares of Exelixis, Shares Up 6.1% (EXEL)
Comtex SmarTrend(R) - Thu Jul 24, 10:38AM CDT
Exelixis (NASDAQ:EXEL) is one of today's best performing low-priced stocks, up 6.1% to $4.01 on 1.0x average daily volume. Thus far today, Exelixis has traded 4.8 million shares, vs. average volume of 4.7 million shares per day. The stock has outperformed the Dow (6.1% to the Dow's 0.1%) and outperformed the S&P 500 (6.1% to the S&P's 0.2%) during today's trading.
Is this Exelixis Stock's Worst Nightmare?
Cory Renauer, The Motley Fool - Motley Fool - Tue Jul 22, 4:00PM CDT
Oncology specialist Exelixis shares have been on a roller coaster over the past several years. The company has an impressive stable of clinical stage candidates, but its pipeline has yet to prove itself in the clinic, or on the market. Having lots...
This Week in Biotech: AbbVie's Five-Leaf Clover and Exelixis' Excellent Results
Sean Williams, The Motley Fool - Motley Fool - Sat Jul 19, 1:32PM CDT
With the SPDR S&P Biotech Index up 18% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
SEC Filings, Positive Trial Results, Technical Updates, and sNDA Updates - Analyst Notes on Questcor, Exelixis, InterMune, Progenics and Arrowhead
PR Newswire - Fri Jul 18, 7:40AM CDT
Today, Analysts Review released its analysts' notes regarding Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Exelixis, Inc. (NASDAQ: EXEL), InterMune Inc. (NASDAQ: ITMN), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX) and Arrowhead Research Corp. (NASDAQ: ARWR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4874-100free.
Exelixis, Inc., Analyst Report; The Upside Potential is Worth the Risk by BrokerBank Securities, Inc.
PR Newswire - Thu Jul 17, 2:05PM CDT
Exelixis, Inc. (Nasdaq: EXEL) is a development stage biotech company. EXEL developed two cancer treatments cabozantinib (Cabo, Cometriq) and cobimetinib (Cobi). Both use small molecules as the active component. The company has a partnership with Roche to commercialize, market and distribute cobi. Cobi is expected to earn approval in the treatment of melanoma by late 2015, after positive phase-three trial results earlier this week. Cabo is marketed and distributed in the U.S. by EXEL, and in Europe by Sobi. Sobi receives an undisclosed management fee. European revenues are expected in Q2 after a March European approval. Cabo is currently only approved to treat a specific type of thyroid cancer, MTC. There are between 500-700 new cases per year in the U.S., and treatment costs $10,395 for a 28-day supply. In addition, the company has five phase-three trials for various cancer treatments. On top of those, the company has numerous partnerships with other drug companies, and multiple treatments in phase two trials. EXEL has a huge pipeline of potential uses for cabo and cobi.
Should Roche Buy Exelixis?
Stephen D., Simpson,, The Motley Fool - Motley Fool - Wed Jul 16, 4:00PM CDT
Investors in Roche and Exelixis saw a bit of positive news Monday, when Roche announced that its phase 3 combo study of MEK inhibitor cobimetinib (licensed from Exelixis) and BRAF inhibitor Zelboraf met it primary endpoint. No details were...
Exelixis to Release Second Quarter 2014 Financial Results on Thursday, July 31, 2014
Business Wire - Wed Jul 16, 3:05PM CDT
Exelixis, Inc. (NASDAQ: EXEL) announced today that its second quarter 2014 financial results will be released on Thursday, July 31, 2014 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call to discuss the Company's financial results for the second quarter 2014 and provide a general business update. The conference call will be accessible via the Internet from the Company's website.
Time to Fall Back in Love With Exelixis Inc.?
Brian Orelli, The Motley Fool - Motley Fool - Tue Jul 15, 4:34PM CDT
Exelixis spiked up 23% Monday after its partner Roche announced that the duo's cancer drug passed a phase 3 trial. Some speculation about a potential buyout by Roche also seems to have contributed to Exelixis' increased value. Let's cover...
Most active Nasdaq-traded stocks
AP - Tue Jul 15, 12:20PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
Critical Alerts For Exelixis, Rocket Fuel, Netflix, Johnson & Johnson, and Achillion Pharmaceuticals Released By InvestorsObserver
PR Newswire - Tue Jul 15, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for EXEL, FUEL, NFLX, JNJ, and ACHN.
Exelixis (EXEL) Soars: Stock Adds 23% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 15, 8:04AM CDT
Exelixis, Inc. (EXEL) was a big mover last session, as the company saw its shares rise 23% on the day.
